4.3 Article

Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword

期刊

IMMUNOBIOLOGY
卷 222, 期 1, 页码 89-100

出版社

ELSEVIER GMBH, URBAN & FISCHER VERLAG
DOI: 10.1016/j.imbio.2016.06.009

关键词

TLR; Immune cells; Tumor cells; Pro-tumoral effect; Anti-tumoral effect; TLR signaling

资金

  1. Institut National de la Sante et de la Recherche Medicale
  2. Fondation ARC pour la recherche sur le cancer
  3. Fondation de France [00012068]
  4. Universite Pierre et Marie Curie
  5. Universite Paris-Descartes
  6. Institut National du Cancer [2011-1-PLBIO-06-INSERM 6-1, PLBIO09-088-IDF-KROEMER]
  7. CARPEM (CAncer Research for PErsonalized Medicine)
  8. Labex Immuno-Oncology

向作者/读者索取更多资源

Toll-like receptors (TLRs) are a family of transmembrane receptors that recognize various pathogen- and damage-associated molecular pattern molecules playing an important role in inflammation by activating NF-kappa B. TLRs, mainly expressed by innate immune cells, are involved in inducing and regulating adaptive immune responses. However, the expression of TLRs has also been observed in many tumors, and their stimulation results in tumor progression or regression, depending on the TLR and tumor type. Here we review the role of TLRs in conferring anti- or pro-tumoral effects. The anti-tumoral effects can result from direct induction of tumor cell death and/or activation of efficient anti-tumoral immune responses, and the pro-tumoral effects may be due to inducing tumor cell survival and proliferation or by acting on suppressive or inflammatory immune cells in the tumor microenvironment. (C) 2016 Elsevier GmbH. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+double positive T cell density in locally advanced N2 non-small-cell lung carcinoma

G. Boulle, Y. Velut, A. Mansuet-Lupo, L. Gibault, H. Blons, L. Fournel, A. Boni, I. Cremer, M. Wislez, V. Duchatelle, J. Tredaniel, S. A. Hammond, R. Herbst, M. Alifano, P. Giraud, D. Damotte

EUROPEAN JOURNAL OF CANCER (2020)

Review Immunology

NK cells in the tumor microenvironment: Prognostic and theranostic impact. Recent advances and trends

Jules Russick, Carine Torset, Edouard Hemery, Isabelle Cremer

SEMINARS IN IMMUNOLOGY (2020)

Article Oncology

Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions

Jules Russick, Pierre-Emmanuel Joubert, Melanie Gillard-Bocquet, Carine Torset, Maxime Meylan, Florent Petitprez, Marie-Agnes Dragon-Durey, Solenne Marmier, Aditi Varthaman, Nathalie Josseaume, Claire Germain, Jeremy Goc, Marie-Caroline Dieu-Nosjean, Pierre Validire, Ludovic Fournel, Laurence Zitvogel, Gabriela Bindea, Audrey Lupo, Diane Damotte, Marco Alifano, Isabelle Cremer

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Article Medicine, Research & Experimental

Immunodynamics of explanted human tumors for immuno-oncology

Agathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaelle Goubet, Safae Terrisse, Nicolas Voisin, Charles Bayard, Sebastien Lofek, Damien Drubay, Delphine Bredel, Severine Mouraud, Sandrine Susini, Alexandria Cogdill, Lucas Rebuffet, Elise Ballot, Nicolas Jacquelot, Vincent Thomas de Montpreville, Odile Casiraghi, Camelia Radulescu, Sophie Ferlicot, David J. Figueroa, Sapna Yadavilli, Jeremy D. Waight, Marc Ballas, Axel Hoos, Thomas Condamine, Bastien Parier, Christophe Gaudillat, Bertrand Routy, Francois Ghiringhelli, Lisa Derosa, Ingrid Breuskin, Mathieu Rouanne, Fabrice Andre, Cedric Lebacle, Herve Baumert, Marie Wislez, Elie Fadel, Isabelle Cremer, Laurence Albiges, Birgit Geoerger, Jean-Yves Scoazec, Yohann Loriot, Guido Kroemer, Aurelien Marabelle, Melodie Bonvalet, Laurence Zitvogel

Summary: Decision making in immuno-oncology plays a crucial role in adapting therapy to the tumor microenvironment. A multiplex functional and dynamic immuno-assay has been developed to predict unresponsiveness to anti-PD-1 mAbs and detect personalized combinatorial regimens in human primary tumors, awaiting validation in prospective clinical trials.

EMBO MOLECULAR MEDICINE (2021)

Article Multidisciplinary Sciences

Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity

Marie-Agnes Dragon-Durey, Xiaoyi Chen, Amos Kirilovsky, Nadine Ben Hamouda, Carine El Sissy, Jules Russick, Etienne Charpentier, Yannick Binois, Florence Marliot, Maxime Meylan, Clemence Granier, Helene Pere, Antonin Saldmann, Bastien Rance, Anne Sophie Jannot, Stephanie Baron, Mouna Chebbi, Antoine Fayol, Nathalie Josseaume, Claire Rives-Lange, Pierre-Louis Tharaux, Bernard Cholley, Jean-Luc Diehl, Jean-Benoit Arlet, Michel Azizi, Alexandre Karras, Sebastien Czernichow, David M. Smadja, Jean-Sebastien Hulot, Isabelle Cremer, Eric Tartour, Elie Mousseaux, Franck Pages

Summary: This study investigated the mechanisms underlying SARS-CoV-2 infection severity in patients with obesity. It found specific associations between inflammatory cytokines and liver, renal, and endothelial dysfunctions in obese patients, and independent correlations between early lung damage and obesity with cytokine levels. These findings highlight distinct pathophysiological mechanisms associated with SARS-CoV-2 infection in obese patients.

PLOS ONE (2021)

Article Oncology

Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade

Marie V. Daugan, Margot Revel, Romane Thouenon, Marie-Agnes Dragon-Durey, Tania Robe-Rybkine, Carine Torset, Nicolas S. Merle, Remi Noe, Virginie Verkarre, Stephane Marie Oudard, Arnaud Mejean, Pierre Validire, Xavier Cathelineau, Rafael Sanchez-Salas, Mathew C. Pickering, Isabelle Cremer, Audrey Mansuet-Lupo, Marco Alifano, Catherine Sautes-Fridman, Diane Damotte, Wolf H. Fridman, Lubka T. Roumenina

Summary: The study reveals the impact mechanism of the master complement regulator factor H (FH) in clear cell renal cell carcinoma and lung cancer. FH exerts a protumoral action through an intracellular, noncanonical mechanism, affecting cell proliferation, migration, and cell cycle regulation. Intracellular FH plays a role in tumor progression in specific types of cancer, suggesting its potential as a prognostic biomarker or therapeutic target.

CANCER IMMUNOLOGY RESEARCH (2021)

Article Oncology

Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s

Marie V. Daugan, Margot Revel, Jules Russick, Marie-Agnes Dragon-Durey, Christine Gaboriaud, Tania Robe-Rybkine, Victoria Poillerat, Anne Grunenwald, Guillaume Lacroix, Antoine Bougouin, Maxime Meylan, Virginie Verkarre, Stephane M. Oudard, Arnaud Mejean, Yann A. Vano, Geraldine Perkins, Pierre Validire, Xavier Cathelineau, Rafael Sanchez-Salas, Diane Damotte, Veronique Fremeaux-Bacchi, Isabelle Cremer, Catherine Sautes-Fridman, Wolf H. Fridman, Lubka T. Roumenina

Summary: The complement system and C1s play important roles in clear cell renal cell carcinoma, with high C1s expression potentially promoting tumor progression.

CANCER IMMUNOLOGY RESEARCH (2021)

Article Immunology

Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine

Jules Russick, Pierre-Emmanuel Foy, Nathalie Josseaume, Maxime Meylan, Nadine Ben Hamouda, Amos Kirilovsky, Carine El Sissy, Eric Tartour, David M. Smadja, Alexandre Karras, Jean-Sebastien Hulot, Marine Livrozet, Antoine Fayol, Jean-Benoit Arlet, Jean-Luc Diehl, Marie-Agnes Dragon-Durey, Franck Pages, Isabelle Cremer

Summary: Analysis of immune biomarkers in hospitalized COVID-19 patients reveals two categories, with those showing abnormal immune responses experiencing more severe disease. A proposed SARS-Score based on quantifiable biomarkers allows for classification and tailored treatment based on immune profile upon hospital admission.

FRONTIERS IN IMMUNOLOGY (2021)

Article Oncology

Metabolic features of cancer cells impact immunosurveillance

Adrien Joseph, Pan Juncheng, Michele Mondini, Nizar Labaied, Mauro Loi, Julien Adam, Antoine Lafarge, Valentina Astesana, Florine Obrist, Christophe Klein, Norma Bloy, Gautier Stoll, Nicolas Signolle, Catherine Genestie, Diane Damotte, Marco Alifano, Alexandra Leary, Patricia Pautier, Philippe Morice, Sebastien Gouy, Eric Deutsch, Cyrus Chargari, Marie-Caroline Dieu-Nosjean, Isabelle Cremer, Judith Michels, Guido Kroemer, Maria Castedo

Summary: Tumors adapt their metabolism to resist therapeutic interventions like cisplatin, affecting the local immunosurveillance. This study found that PDXK and PAR levels impact the response to cisplatin, providing new insights into therapeutic failures in cancer treatment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Review Medicine, Research & Experimental

Autophagy modulation by viruses: An important role in tumor progression

Lucas Leonardi, Sophie Siberil, Marco Alifano, Isabelle Cremer, Pierre-Emmanuel Joubert

Summary: Autophagy is a crucial process for cellular homeostasis and plays a dual role in tumor progression. It can limit early-stage carcinogenesis while promoting tumor growth and therapy resistance at later stages. Viral infections can modulate autophagy and have significant impacts on tumor behavior.

M S-MEDECINE SCIENCES (2022)

Review Oncology

Autophagy Modulation by Viral Infections Influences Tumor Development

Lucas Leonardi, Sophie Siberil, Marco Alifano, Isabelle Cremer, Pierre-Emmanuel Joubert

Summary: Autophagy plays a crucial role in tumor development, influencing tumor transformation, survival, and resistance to treatment. Additionally, the association between viral infection and autophagic modulation can impact tumor behavior by affecting the fate of tumor cells.

FRONTIERS IN ONCOLOGY (2021)

Article Oncology

Autophagy-Related Gene Signature Highlights Metabolic and Immunogenic Status of Malignant Cells in Non-Small Cell Lung Cancer Adenocarcinoma

Lucas Leonardi, Sophie Siberil, Marco Alifano, Isabelle Cremer, Pierre-Emmanuel Joubert

Summary: The role of autophagy in lung cancer is still debated. This study focuses on the expression of autophagy genes in lung cancer patients and identifies an autophagy signature that correlates with the metabolic and immunogenic status of malignant cells. These findings support the relationship between autophagy and tumor growth in lung cancer patients.

CANCERS (2022)

News Item Oncology

COMPLEMENTing immunotherapy

Lubka T. Roumenina, Isabelle Cremer

Summary: A new study shows that intratumoral activation of the complement cascade may be a potential therapy for lung cancer patients with strong EGFR signaling. The expression of CD55 and CD59 triggered by EGFR prevents opsonization of tumor cells, inhibits antitumor immunity, and confers resistance to immune-checkpoint inhibitors.

NATURE CANCER (2022)

Article Oncology

SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+cells and neutrophils

Yoan Velut, Elise Decroix, Helene Blons, Marco Alifano, Karen Leroy, Florent Petitprez, Aurelie Boni, Simon Garinet, Jerome Biton, Isabelle Cremer, Marie Wislez, Pascaline Boudou-Rouquette, Jennifer Arrondeau, Francois Goldwasser, Ludovic Fournel, Diane Damotte, Audrey Mansuet-Lupo

Summary: SMARCA4/BRG1 loss is common in NSCLC and is associated with high-grade adenocarcinomas and pleomorphic carcinomas. SD-NSCLC patients have an immunosuppressive environment characterized by increased FOXP3+ cells and neutrophil densities. SD-NSCLC patients have a poor prognosis and limited response to PD1 inhibitors.

LUNG CANCER (2022)

Meeting Abstract Oncology

Radio-chemotherapy efficacy is predicted by intra-tumor CD8+FoxP3+double positive T cell density in locally advanced non-small cell lung carcinoma

Yoan Velut, Geoffroy Boulle, Audrey Mansuet Lupo, Laure Gibault, Helene Blons, Jean Tredaniel, Ludovic Fournel, Aurelie Boni, Isabelle Cremer, Marie Wislez, Veronique Duchatelle, Scott Hammond, Marco Alifano, Philippe Giraud, Diane Damotte

CANCER RESEARCH (2020)

暂无数据